Abstract
Chronic kidney disease carries a very high mortality risk, in particular from cardiac diseases. Often heart failure and renal failure coincide, a phenomenon referred to as the cardio renal syndrome. In recent years, it has become clear that not only fibrotic repair but also restoration of damaged kidney and heart can occur and the use of cell therapy has been advanced as a means to activate endogenous repair mechanisms or even to re-introduce repairing tissue. In this perspective, mesenchymal stromal cells are of particular interest, since these cells have both immune modulating and reparative functions and are on the brink of entering the clinical arena. Indeed, MSCs can trigger numerous therapeutic biologic processes that contribute to both renal and cardiac repair; however exact mechanisms of actions are largely unknown. In the present review we have made a critical appraisal of the data available with respect to origin and function of MSCs, and we discuss both preclinical as well as clinical evidence on their therapeutic potential in kidney and heart disease.
Keywords: Mesenchymal stromal cells, renal disease, cardiac disease, organogenesis, repair, immune modulation.
Current Pharmaceutical Design
Title:Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Volume: 20 Issue: 14
Author(s): Marlies E.J. Reinders, Danielle G. Leuning, Johan W. de Fijter, Martin.J. Hoogduijn and Ton J. Rabelink
Affiliation:
Keywords: Mesenchymal stromal cells, renal disease, cardiac disease, organogenesis, repair, immune modulation.
Abstract: Chronic kidney disease carries a very high mortality risk, in particular from cardiac diseases. Often heart failure and renal failure coincide, a phenomenon referred to as the cardio renal syndrome. In recent years, it has become clear that not only fibrotic repair but also restoration of damaged kidney and heart can occur and the use of cell therapy has been advanced as a means to activate endogenous repair mechanisms or even to re-introduce repairing tissue. In this perspective, mesenchymal stromal cells are of particular interest, since these cells have both immune modulating and reparative functions and are on the brink of entering the clinical arena. Indeed, MSCs can trigger numerous therapeutic biologic processes that contribute to both renal and cardiac repair; however exact mechanisms of actions are largely unknown. In the present review we have made a critical appraisal of the data available with respect to origin and function of MSCs, and we discuss both preclinical as well as clinical evidence on their therapeutic potential in kidney and heart disease.
Export Options
About this article
Cite this article as:
Reinders E.J. Marlies, Leuning G. Danielle, Fijter W. de Johan, Hoogduijn Martin.J. and Rabelink Ton J., Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders, Current Pharmaceutical Design 2014; 20(14) . https://dx.doi.org/10.2174/13816128113199990477
DOI https://dx.doi.org/10.2174/13816128113199990477 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions
Current Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Detection and Treatment of Alcohol-Induced Hypertension
Current Hypertension Reviews Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Editorial (Thematic Issue: Advanced Biomaterial in Clinical Medicine)
Current Medicinal Chemistry Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology